Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.

International Journal of Molecular Sciences
Magdalena OlbrytWiesława Widłak

Abstract

Modern immunotherapy together with targeted therapy has revolutionized the treatment of advanced melanoma. Inhibition of immune checkpoints significantly improved the median overall survival and gave hope to many melanoma patients. However, this treatment has three serious drawbacks: high cost, serious side effects, and an effectiveness limited only to approximately 50% of patients. Some patients do not derive any or short-term benefit from this treatment due to primary or secondary resistance. The response to immunotherapy depends on many factors that fall into three main categories: those associated with melanoma cells, those linked to a tumor and its microenvironment, and those classified as individual ontogenic and physiological features of the patient. The first category comprises expression of PD-L1 and HLA proteins on melanoma cells as well as genetic/genomic metrics such as mutational load, (de)activation of specific signaling pathways and epigenetic factors. The second category is the inflammatory status of the tumor: "hot" versus "cold" (i.e., high versus low infiltration of immune cells). The third category comprises metabolome and single nucleotide polymorphisms of specific genes. Here we present up-to-date data on ...Continue Reading

References

Jun 24, 1998·The Journal of Clinical Investigation·D J HicklinS Ferrone
Mar 20, 2002·Cytokine & Growth Factor Reviews·Hiroaki IkedaRobert D Schreiber
Jun 28, 2006·The Journal of Experimental Medicine·Hidetoshi SumimotoYutaka Kawakami
Dec 8, 2011·Cancer Immunology, Immunotherapy : CII·Rui-Ru JiVafa Shahabi
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Aug 2, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jahan S KhaliliGregory Lizée
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Aug 30, 2013·Science Translational Medicine·Stefani SprangerThomas F Gajewski
Nov 7, 2013·Frontiers in Immunology·Patrick A Ott, Nina Bhardwaj
May 17, 2014·PloS One·Maria C WhelanMark Tangney
Oct 9, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antje SuckerAnnette Paschen
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Jan 15, 2015·Epigenetics : Official Journal of the DNA Methylation Society·Debina SarkarMarjan E Askarian-Amiri
Feb 20, 2015·Molecular Cancer Therapeutics·Sandip Pravin Patel, Razelle Kurzrock
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Aug 25, 2015·Cancer Immunology Research·David M WoodsJeffrey Weber
Aug 28, 2015·American Journal of Physiology. Cell Physiology·Muhammad Zaeem NomanSalem Chouaib
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Oct 31, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Zhengxiao OuyangGang Huang
Nov 7, 2015·Science·Marie VétizouLaurence Zitvogel
Nov 26, 2015·Trends in Immunology·Andy J Minn
Dec 10, 2015·Cancer Discovery·Weiyi PengPatrick Hwu
Apr 16, 2016·Nature Reviews. Cancer·Suzanne L TopalianDrew M Pardoll
Jun 4, 2016·Journal of Leukocyte Biology·Anna E VilgelmAnn Richmond
Jul 20, 2016·The New England Journal of Medicine·Jesse M ZaretskyAntoni Ribas
Aug 31, 2016·OncoTargets and Therapy·Xin WangJinming Yu
Nov 20, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adil I DaudOmid Hamid
Dec 14, 2016·The New England Journal of Medicine·Eric TranSteven A Rosenberg
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas
Mar 3, 2017·Immunity, Inflammation and Disease·Scott A FisherRichard A Lake
Mar 21, 2017·Handbook of Experimental Pharmacology·Rodrigo N RamosEmanuela Romano

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing
histone acetylation
PBAF

Clinical Trials Mentioned

NCT03829332

Software Mentioned

Immunoscore

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.